Liping Dou
Clinical trials sponsored by Liping Dou, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New CAR-T therapy aims to keep leukemia in remission Results expected Dec 2026 (estimated)
- New CAR-T therapy aims to keep High-Risk leukemia in remission Results expected Dec 2026 (estimated)
- Engineered immune cells aim to deepen remission in lymphoma patients Results expected Jan 2027 (estimated)
- Can engineered immune cells lock in remission for aggressive lymphoma? Results expected Apr 2027 (estimated)
-
Can a drug duo keep High-Risk blood cancers at bay after transplant?
Disease control OngoingThis early-phase trial is exploring whether combining two drugs, selinexor and azacitidine, can help prevent relapse in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who carry a TP53 mutation and have already undergone a stem cell transplant…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThis phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…
Phase 2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC